DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Rummel MJ. et al
Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany)
Blood. 2009; 114 (22): 168 (abstract 405), oral presentation at ASH 2009;
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.